Navigation Links
Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
Date:12/6/2012

nd is being developed for the treatment of cognitive disorders, including schizophrenia where OMS824 could also have a beneficial effect on the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of the disease.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, Omeros' expectations regarding when it will announce the remaining data from its Phase 1 clinical trial evaluating OMS824; that it will announce Phase 3 data from its OMS103HP program this month; that it will submit an NDA next quarter for OMS302; that as many as three additional programs will enter the clinic in 2013; and that Omeros may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information availa
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
2. Omeros is Not Aware of Any Justification for Share Price Movement
3. Omeros Corporation Reports Third Quarter 2012 Financial Results
4. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
5. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
6. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
7. Omeros to Present at Two Upcoming Conferences
8. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Discovery in MASP-2 Program
11. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
(Date:1/14/2014)... , Jan. 14, 2014 Animal Emergency Critical Care, a LifeCentre ... Leesburg, Virginia is the first in Loudoun ... Dr. Susan M. Barnes , Medical Director, ... and husband, Dr. Cole Taylor , are avid scuba divers. ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... ANTONIO, Feb. 28, 2011 Advanced Cell Diagnostics, ... clinical study utilizing RNAscope™ technology to detect human ... of head and neck cancer. HPV status determined ... of patient outcome and highly concordant with that ...
... 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) ... dividend policy for 2011 and beyond and declared that the four ... be $0.15 per share of common stock.  The $0.15 dividends will ... 15 to all stockholders who own shares of PDL on March ...
Cached Medicine Technology:ACD Announces Clinical Study Results Using its RNAscope™ Technology 2ACD Announces Clinical Study Results Using its RNAscope™ Technology 3PDL BioPharma Announces Regular Quarterly Dividend Policy 2
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... relief targets that could be used to provide ... College London made the discovery when researching how ... the body. , Dr Marzia Malcangio said: "We ... generation and our findings could help chemotherapy patients ... potential side effect of some chemotherapy drugs (such ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
(Date:4/17/2014)... (April 16, 2014) The cause of neuronal death ... study proposes that neurons may be mistaken for foreign ... similar to the way autoimmune diseases like type I ... cells. The study was published April 16, 2014, in ... and likely controversial, idea in Parkinson,s disease; but if ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
... 2 Bob Hickman, United Feather & Down,s Senior Vice ... Inc.,s Vice President of Marketing, list their top sleep and ... four times faster than water, and its super emollient qualities ... bedding is kind to your skin to help you awaken ...
... , MIAMI, Oct. 2 The American Lung Association of ... Influenza initiative by conducting a public influenza panel discussion ... influenza and the importance of annual vaccination. The meeting will ... among high-risk groups. , The recent A (H1N1) outbreak ...
... Rising Medical Solutions, Inc. (Rising), a leading medical-financial solutions ... Company Index (PCI) "Top 10 Growth Companies" list. This ... honoree, making it the longest running Company to achieve ... , Comments Stephen H. Watkins, CEO of PCI sponsor ...
... , LEE,S SUMMIT, Mo., Oct. 2 R&D/Leverage,s ... integrated under one roof - continue to expand in ... the company,s Vice President - Engineering. , According to ... technical and engineering staff, new lean initiatives and quality-control ...
... LAS VEGAS, Oct. 2 Cord Blood America, Inc. ... cell preservation company ( http://www.cordblood-america.com ) ... cells, a biological insurance policy, to families nationwide and ... principal amount $160,000, in its continuing effort to reduce ...
... World Vision, one of the world,s leading emergency response ... be a wake-up call to the global community to fund ... agency, an expert in disaster risk reduction (DRR), works with ... to disasters like earthquakes and tsunamis, and says that DRR ...
Cached Medicine News:Health News:Ten from Two: Top Sleep and Beauty Tips from the Experts 2Health News:Ten from Two: Top Sleep and Beauty Tips from the Experts 3Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 2Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 3Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 4Health News:American Lung Association of Florida-South Area Encourages Miami Residents to See Themselves Among the Many 'Faces' of Influenza 5Health News:Rising Medical Solutions First to Achieve Six Consecutive Rankings on the Private Company Index 2Health News:R&D/Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 2Health News:R&D/Leverage Heightens Investment in Medical and Silicone Mold Manufacturing 3Health News:Cord Blood America Retires Note in Continuing Effort to Reduce Debt 2Health News:World Vision Says Asian Disasters Should Be 'Wake-Up Call' For Global Leaders 2Health News:World Vision Says Asian Disasters Should Be 'Wake-Up Call' For Global Leaders 3
... SST™ Tubes contain spray-coated ... gel for serum separation. ... serum determinations in chemistry. ... efficient means of serum ...
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry....
MONOJECT Red/Yellow Mottled Stopper...
BD Vacutainer® Specialty Tubes - Thrombin...
Medicine Products: